drugset / Trial / NCT04143815
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.
Timeline
- Start
- 2019-05-20
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBA-P01 | Protein / enzyme biologic | 10 iu | Intramuscular |
| Subject | MBA-P01 | Protein / enzyme biologic | 20 iu | Intramuscular |
| Subject | MBA-P01 | Protein / enzyme biologic | 30 iu | Intramuscular |
Indications
No indication recorded.